Optellum Virtual Nodule Clinic vs Ultromics EchoGo

Optellum's single openFDA decision covers CT lung nodules, with a CADx function reserved for pulmonologists and radiologists. Ultromics works on transthoracic echocardiography and holds six decisions, with EchoGo Heart Failure (K240013) and EchoGo Amyloidosis (K240860) as the products on its pages. A nodule on CT and an HFpEF flag on a four-chamber clip answer different clinical questions in different departments.

Pulmonology-led nodule clinics, such as the Penn Medicine and Vanderbilt sites named on Optellum's site, are Optellum's customers. Cardiology echo labs, such as the Mayo Clinic and UChicago Medicine sites Ultromics lists, are Ultromics' customers. The vendor says Ultromics routes studies through standard DICOM workflows with no on-premise infrastructure and returns findings to PACS and EMR typically within 20 minutes. On the funding side, Optellum announced a Series B on January 8, 2026 with Woori Venture Partners and Healthliant Ventures, and Ultromics announced a Series C on July 31, 2025.